Rare blood disease patients get continued access to experimental treatment
NCT ID NCT06028594
Summary
This program provides continued access to an experimental two-drug combination (pozelimab and cemdisiran) for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare disease where the immune system destroys red blood cells. It's specifically for patients who have already completed certain previous clinical trials of this treatment. The main goal is to document the long-term safety of this combination therapy while providing access to it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.